Alzheimer’s Care Innovation: Advancing Implementation Across Europe

Pioneering Alzheimer’s Care Innovation in Europe

Alzheimer’s care innovation is transforming Europe’s approach to the disease, shifting from policy discussions to real-world implementation of disease-modifying therapies. With 10 million Europeans affected amid an aging population, recent regulatory approvals mark a critical juncture, demanding practical delivery through health systems. Sustained multi-stakeholder collaboration is vital to convert scientific breakthroughs into equitable, sustainable benefits for patients, as explored in this EFPIA perspective.

Health system readiness for integrating new disease-modifying therapies requires closer examination, particularly the move from planning to action. Early detection remains uneven across Member States, with primary-care-led screenings and multidisciplinary memory clinics often delayed. Promising developments include pilots of digital assessment tools and data-informed models, highlighted in the EFPIA Alzheimer’s Disease Platform’s 2025 blueprint on person-centered care. These innovations, showcased in scalable sessions during EFPIA Life Sciences Week, unite industry, policymakers, and experts to tackle barriers like fragmented regulatory and reimbursement processes, which risk widening socioeconomic gaps in access.

The diagnostic divide persists, with varying capacities underscoring the need for enhanced monitoring and follow-up. The Platform’s stakeholder consultations and blueprint provide evidence-based solutions, such as patient registries discussed at the December 2025 HMA-EMA workshop. This Alzheimer’s care innovation approach ensures proactive, data-driven pathways, enabling long-term evidence for refining post-approval strategies.

Accelerating EU-Level Policy Momentum

The political evolution treating Alzheimer’s as an urgent EU priority, was sparked by the September 2025 European Parliament debate. This signals a pivot from long-term societal concerns to coordinated action, bolstered by the EFPIA Platform’s events fostering system-wide integration over siloed efforts. Cross-border learning, as compiled in the blueprint’s best practices for care pathways, exposes regulatory fragmentation but spotlights progress via joint workshops on registries involving regulators, patients, and payers to build robust real-world evidence.

Drawing from the Platform’s 2025 activities, including the December scaling innovation webinar, these multi-disciplinary efforts demonstrate strengths in collaboration while addressing regional disparities in implementation, such as diagnostic inequities between Member States.

Unlocking Economic Value Through Equitable Access

Streamlined regulatory and HTA pathways support value-based therapies reaching patients. Early diagnostics could also yield billions in savings by curbing institutionalization—mirroring oncology successes. Patient registries and real-world evidence will strengthen HTA submissions, enabling payment models that link to reduced payer risks for Alzheimer’s interventions. These dynamics ofcourse influence pricing, where disjointed access could stall pipeline investments without EU harmonization under the HTA Regulation. This fosters sustainable market entry, advancing Alzheimer’s care innovation to reach diverse populations and mitigate socioeconomic inequities.